How to create a problem list governance strategy

Problem list governance doesn’t just happen. It’s the responsibility of multiple stakeholders and requires a thoughtful, flexible strategy. Learn more below.
Published
Written by
Picture of Barbi Green
Vice President, Brand and Content

The medical problem list, while imperfect, is an essential tool for clinicians. When used and maintained properly, it can provide an important snapshot of a patient’s current diagnoses and significant health issues. However, without clear rules on how to manage and maintain problem lists, they can quickly grow outdated and unruly.

On a patient level, a cluttered list can impact the quality of care. For physicians, it is easy to imagine the frustration and cognitive burden of sifting through outdated, redundant, or irrelevant data. And at an organizational level, the ripple effects can be felt from scheduling to billing and beyond.

The reality is that a cluttered problem list is everyone’s problem. But whose job is it to fix?

While there are solutions that can help – IMO Core being one – there’s really no easy answer when it comes to assigning roles and responsibilities. However, our new how-to guide outlines four key considerations for developing a problem list governance strategy that can be adapted to organizations of any size.

  1. Define organizational goals
  2. Create a governance task force
  3. Establish rules of engagement
  4. Follow up and refine

If it’s time to move from an every-clinician-for-themselves mentality to a more holistic, thoughtful approach, you’ve found a great place to start.   

Get your organization on the path to more meaningful, manageable, and useful patient information with our how-to guide, Creating a problem list governance strategy.

Rather watch than read? Check out this on-demand webinar.

Related Content

Latest Resources​

Learn why our industry-leading clinical terminology and dedication to data quality earned IMO Health two Best in Business Awards from Modern Healthcare.
The FDA has provided direction on the use of AI for drug and biologic development. Here’s what life sciences teams should know.
Get the full scoop on the new CMS TEAM model, including what it is, why it matters, and how to ensure readiness.
ICYMI: BLOG DIGEST

The latest insights and expert perspectives from IMO Health

In your inbox, twice per month.